Kunming Qi
Overview
Explore the profile of Kunming Qi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li N, An N, Ma S, Cao J, Zhu F, Qi K, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(5):148.
PMID: 40088299
Factors associated with outcomes of chimeric antigen receptor (CAR)-T cell therapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have not been fully elucidated. We explored...
2.
Hu X, Yu X, Zhang L, Zhang Q, Ji M, Qi K, et al.
Exp Cell Res
. 2024 Dec;
444(2):114377.
PMID: 39706286
Aurora kinase B (AURKB) was reported to assist Aurora kinase A (AURKA) to regulate cellular mitosis. AURKA has been found activated in myeloproliferative neoplasms (MPNs) patients with CALR gene mutation,...
3.
Cheng H, Shao L, Wang D, Chen Y, Sun Y, Chen Z, et al.
Cytotherapy
. 2024 Sep;
27(1):16-24.
PMID: 39283287
Background: Many studies have demonstrated the effectiveness of chimeric antigen receptor-T (CAR-T) cell therapy for relapsed or refractory multiple myeloma (RRMM), but the hematologic toxicity has not been well characterized....
4.
Ma R, Zhang Q, Liu Y, Li H, Chen H, Zhang Q, et al.
Clin Exp Med
. 2024 Sep;
24(1):210.
PMID: 39230837
The influence of chimeric antigen receptor T (CAR-T) cell therapy on platelet function in relapsed/refractory (R/R) multiple myeloma (MM) has not been thoroughly investigated. Our cohort comprised fifty MM patients...
5.
Qi Y, Li H, Qi K, Zhu F, Cheng H, Chen W, et al.
Am J Hematol
. 2024 Aug;
99(12):2286-2295.
PMID: 39194355
Relapsed/refractory multiple myeloma patients with extramedullary disease (EMD) have unfavorable prognosis and lack effective therapy. Chimeric antigen receptor (CAR) T-cell activities in EMD have yet to be determined; how EMD-specific...
6.
Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, et al.
Lancet Haematol
. 2024 Jul;
11(10):e751-e760.
PMID: 39059405
Background: Some challenges still exist with single-target B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies due to variable or negative BCMA expression, although they have yielded remarkable efficacy...
7.
Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, et al.
Nat Commun
. 2024 Apr;
15(1):3371.
PMID: 38643278
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist...
8.
Ma S, Wang Y, Qi K, Lu W, Qi Y, Cao J, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):104.
PMID: 38630258
Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed...
9.
Cheng H, Sun Y, Zhang X, Chen Z, Shao L, Liu J, et al.
Cytotherapy
. 2024 Apr;
26(8):832-841.
PMID: 38625072
Background Aims: Chimeric antigen receptor-T (CAR-T) cells have exhibited remarkable efficacy in treating refractory or relapsed multiple myeloma (R/R MM). Although obesity has a favorable value in enhancing the response...
10.
Wang Y, Wu D, Zhang X, Li Y, He Y, Liu Q, et al.
BMC Med
. 2024 Mar;
22(1):142.
PMID: 38532458
Background: Chronic graft-versus-host disease (cGVHD) is an immune-related disorder that is the most common complication post-allogenic hematopoietic stem cell transplant. Corticosteroids with or without calcineurin inhibitors (CNIs) remain the mainstay...